SAB Biotherapeutics, Inc. (SABS) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -106.0% |
| FCF Growth (YoY) | 32.0% |
| Price / Book | 1.27 |
| Price / Sales | 78.27 |
| FCF Yield | -5.3% |
| Altman Z-Score | 4.20 (safe) |
| Sector P/E (Healthcare) | 21.7 |
SABS overview · SABS earnings · SABS KPIs · SABS investor relations · SABS ownership · SABS peers · SABS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.